Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective

      We read with great interest the papers recently published in the Journal of Infection tackling the issue of post-vaccination antibody levels to SARS-CoV-2 spike protein.
      • Favresse J.
      • Douxfils J.
      Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination.
      ,
      • Tré-Hardy M.
      • Cupaiolo R.
      • Wilmet A.
      • Beukinga I.
      • Blairon L.
      Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
      Our attention was caught by the report from Favresse and Douxfils
      • Favresse J.
      • Douxfils J.
      Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination.
      showing that high dilution of the tested samples provided a more accurate appreciation of post-vaccination antibody levels. The same authors just published a related study where anti-SARS-CoV-2 serology was followed-up for up to 3 months.
      • Favresse J.
      • Bayart J.L.
      • Mullier F.
      • Elsen M.
      • Eucher C.
      • Eechhoudt S.V.
      • et al.
      Antibody titers decline 3-month post-vaccination with BNT612b2. 202.
      Because they found a significant decrease in day 56 and day 90 antibody levels, they conveyed this notion in the title of their publication. This certainly catchy label can however, in this touchy context, be interpreted as bad news. Here we would like to re-interpret these data in a more positive way by emphasizing the high antibody titers detected in this study.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Favresse J.
        • Douxfils J.
        Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination.
        J Infect. 2021; (S0163-4453(21)00327-3Epub ahead of print)https://doi.org/10.1016/j.jinf.2021.07.001
        • Tré-Hardy M.
        • Cupaiolo R.
        • Wilmet A.
        • Beukinga I.
        • Blairon L.
        Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
        J Infect. 2021; (S0163-4453(21)00314-5)
        • Favresse J.
        • Bayart J.L.
        • Mullier F.
        • Elsen M.
        • Eucher C.
        • Eechhoudt S.V.
        • et al.
        Antibody titers decline 3-month post-vaccination with BNT612b2. 202.
        Emerg Microbes Infect. 2021; 10 (Online ahead of print): 1495-1498https://doi.org/10.1080/22221751.2021.1953403
        • Chevallier P.
        • Coste-Burel M.
        • Le Bourgeois A.
        • Peterlin P.
        • Garnier A.
        • Béné M.C.
        • et al.
        Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.
        EJHaem. 2021; (1:10.1002/jha2.242Epub ahead of print)https://doi.org/10.1002/jha2.242
        • Suhandynata R.T.
        • Bevins N.J.
        • Tran J.T.
        • Huang D.
        • Hoffman M.A.
        • Lund K.
        • et al.
        SARS-CoV-2 Serology status detected by commercialized platforms distinguishes previous infection and vaccination adaptive immune responses.
        J Appl Lab Med. 2021; (jfab080Epub ahead of print)https://doi.org/10.1093/jalm/jfab080
        • Mueller T.
        Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological assays from the same manufacturer.
        Clin Chim Acta. 2021; 518: 9-16
        • Gerhards C.
        • Thiaucourt M.
        • Kittel M.
        • Becker C.
        • Ast V.
        • Hetjens M.
        • et al.
        Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection.
        Int J Infect Dis. 2021; 107: 221-227
        • Moser M.
        • Leo O
        Key concepts in immunology.
        Vaccine, 28. 2010; : C2-13
        • Doria-Rose N.
        • Suthar M.S.
        • Makowski M.
        • O'Connell S.
        • McDermott A.B.
        • Flach B.
        • et al.
        mRNA-1273 Study Group. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19.
        N Engl J Med. 2021; 384: 2259-2261
        • Turner J.S.
        • O'Halloran J.A.
        • Kalaidina E.
        • Kim W.
        • Schmitz A.J.
        • Zhou J.Q.
        • et al.
        SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
        Nature. 2021; (Online ahead of print)https://doi.org/10.1038/s41586-021-03738-2